The bronchiectasis drugs market consists of drugs used for the treatment of bronchiectasis. Bronchiectasis is a respiratory disorder characterized by abnormal, irreversible dilation of part or all of the bronchi in the lungs causing chronic cough with mucus. The increasing prevalence of respiratory diseases such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), and asthma leading to bronchiectasis is a major factor driving the growth of the bronchiectasis drugs market. Drugs used for treatment include macrolides, inhaled corticosteroids, aminoglycosides, hyperosmolar agents, and mucolytics that help reduce sputum production and airway inflammation.
The Global bronchiectasis drugs market is estimated to be valued at US$ 349.98 Bn in 2024 and is expected to exhibit a CAGR of 14.% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the bronchiectasis drugs are Robert Bosch, Denso Corporation, Continental AG, Valeo, ZF Friedrichshafen, Hyundai Mobis, Delphi Automotive, Magna International, Valeo, Hella. Key players are focused on developing new drugs with improved efficacy and better safety profiles through research and development activities. For instance, in 2022, Zambon received FDA approval for Tudorza Pressair (aclidinium bromide inhalation powder) for maintenance treatment of patients with COPD.
The key opportunities in the bronchiectasis drugs market include a large patient pool due to rising prevalence of chronic respiratory diseases, new product launches, and increasing awareness about bronchiectasis treatment. Furthermore, bronchiectasis is more common in developing countries due to poor living conditions and lack of treatment of respiratory infections at early stages presenting significant growth opportunities.
Globally, the Bronchiectasis Drugs Market Size is expanding mainly due to the increasing COPD and cystic fibrosis disease burden. Key market players are focused on expanding their geographic presence especially in Asia Pacific and Latin America regions through collaborations and licensing agreements with regional pharma companies. For instance, in 2022, Delphi Automotive partnered with Hyundai Mobis to set up a joint venture to manufacture electric vehicle components in China to tap the growing EV market.
Market Drivers
High prevalence of chronic respiratory diseases - Increasing incidence of chronic lung diseases such as COPD, asthma, and cystic fibrosis that can lead to bronchiectasis is a major factor promoting the growth of the bronchiectasis drugs market. For instance, according to WHO estimates, over 65 million people have moderate to severe COPD globally.
Availability of new targeted drug therapies - Recent approvals of novel drugs with improved efficacy targeting specific disease pathways is expected to drive the bronchiectasis drug sales. For example, in 2021, FDA approval of the first nebulized antibiotic Arikayce (amikacin liposome inhalation suspension) for refractory Mycobacterium avium complex (MAC) lung disease.
Market Restraints
Low diagnosis rates in developing countries - Lack of awareness about bronchiectasis and limited diagnostic facilities especially in developing nations is a major challenge restricting the bronchiectasis drugs market potential. This leads to most cases remaining undiagnosed at later stages.
High cost of targeted therapies - Many of the novel bronchiectasis treatments provide better efficacy but are also extremely expensive compared to generic medications posing affordability issues. This limits their widespread adoption impacting revenue growth.
Segment Analysis
Bronchiectasis Drugs Market is dominated by the antibiotics segment which holds around 60% share of the total market. Antibiotics are the first line of treatment for bronchiectasis to control infections. Within the antibiotics segment, macrolides sub-segment leads with highest market share due to drugs like azithromycin and erythromycin being effective in reducing exacerbations in patients with bronchiectasis. The anti-inflammatory and mucolytic segments have around 20% share each. Anti-inflammatory drugs segment is growing at fastest rate owing to drugs being increasingly prescribed along with antibiotics to reduce airway inflammation in bronchiectasis.
Global Analysis
North America dominates the global bronchiectasis drugs market with around 45% market share. High prevalence of disease, strong healthcare infrastructure and availability of advanced treatment options drives the North American market. Asia Pacific region is anticipated to witness highest growth during the forecast period owing to rising pollution levels, increasing smoking rates and growing awareness about disease diagnosis and management in developing countries of China and India. Developed markets of Europe will continue to hold significant market share supported by favorable reimbursement policies for newer drugs.
Get more insights on- Bronchiectasis Drugs Market
Herbal Treatment for Bronchiectasis also helps to loosen mucus in the lungs.
Herbal Remedies for Bronchiectasis can prevent damage to the lungs and improve symptoms.
Herbal Treatment for Bronchiectasis read the Symptoms and Causes.
Bronchiectasis is a disease in which there is the permanent enlargement of parts of the airways of the lung.
